BRITTANY SMELSER: Open Payments
NPI 1528555356 · CEDAR RAPIDS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 48 payments from 9 companies in 2025. Trend: 2023 $221 · 2024 $21 · 2025 $896
Food & beverage: $896
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $233 |
| ABBVIE INC. | 13 | $228 |
| Neurocrine BioSciences, Inc. | 7 | $136 |
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| Corium, LLC | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
Products named: VRAYLAR, REXULTI, INGREZZA, COBENFY, CAPLYTA, ABILIFY ASIMTUFII, FANAPT, Azstarys.
Industry payments across IA — which companies pay providers there.
